aTyr Pharma News Releases https://investors.atyrpharma.com/ aTyr Pharma News Releases en aTyr Pharma Announces First Quarter 2019 Results and Provides Corporate Update https://investors.atyrpharma.com/news-releases/news-release-details/atyr-pharma-announces-first-quarter-2019-results-and-provides Phase 1b/2a proof-of-concept clinical trial of ATYR1923 in pulmonary sarcoidosis patients ongoing Advanced lead position in Neuropilin-2 (NRP-2) biology with inaugural NRP-2 summit Company to host conference call and webcast today at 5:00pm EDT / 2:00 PDT SAN DIEGO , May 13, 2019 (GLOBE NEWSWIRE) Mon, 13 May 2019 16:05:00 -0400 aTyr Pharma News Releases 8956 aTyr Pharma to Announce First Quarter 2019 Results on May 13th https://investors.atyrpharma.com/news-releases/news-release-details/atyr-pharma-announce-first-quarter-2019-results-may-13th Company to host conference call and webcast at 5pm EDT / 2pm PDT SAN DIEGO , May 06, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it Mon, 06 May 2019 16:58:00 -0400 aTyr Pharma News Releases 8911 aTyr Pharma to Host Inaugural Summit Meeting on Neuropilin-2 (NRP-2) Biology https://investors.atyrpharma.com/news-releases/news-release-details/atyr-pharma-host-inaugural-summit-meeting-neuropilin-2-nrp-2 Meeting to feature presentations on recent NRP-2-related discoveries by leading research experts in the field SAN DIEGO , April 16, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel Tue, 16 Apr 2019 08:00:00 -0400 aTyr Pharma News Releases 8891 aTyr Pharma Announces $5 Million Registered Direct Offering led by The Federated Kaufmann Small Cap Fund https://investors.atyrpharma.com/news-releases/news-release-details/atyr-pharma-announces-5-million-registered-direct-offering-led SAN DIEGO , April 11, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it has entered into a definitive agreement with The Federated Thu, 11 Apr 2019 08:00:00 -0400 aTyr Pharma News Releases 8876 aTyr Pharma to Present Poster at the American Thoracic Society 2019 International Conference https://investors.atyrpharma.com/news-releases/news-release-details/atyr-pharma-present-poster-american-thoracic-society-2019 ATYR1923 shown to modulate inflammatory and fibrotic processes in multiple interstitial lung disease (ILD) animal models SAN DIEGO , April 08, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based Mon, 08 Apr 2019 16:00:00 -0400 aTyr Pharma News Releases 8871 aTyr Pharma Announces Fourth Quarter and Full Year 2018 Results and Provides Corporate Update https://investors.atyrpharma.com/news-releases/news-release-details/atyr-pharma-announces-fourth-quarter-and-full-year-2018-results Phase 1b/2a proof-of-concept clinical trial of ATYR1923 in pulmonary sarcoidosis patients initiated in December 2018 First tRNA synthetase partnership announced in March 2019 SAN DIEGO , March 25, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the Mon, 25 Mar 2019 16:00:00 -0400 aTyr Pharma News Releases 8841 aTyr Pharma Announces Poster Presentation at the 2019 American Association for Cancer Research (AACR) Annual Meeting https://investors.atyrpharma.com/news-releases/news-release-details/atyr-pharma-announces-poster-presentation-2019-american Abstract Describes Further Evidence that ATYR1923 Modulates Immune Cell Biology SAN DIEGO , March 21, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today Thu, 21 Mar 2019 08:00:00 -0400 aTyr Pharma News Releases 8831 aTyr Pharma to Announce Fourth Quarter and Full Year 2018 Financial Results on March 25th https://investors.atyrpharma.com/news-releases/news-release-details/atyr-pharma-announce-fourth-quarter-and-full-year-2018-financial Company to host conference call and webcast at 5pm EDT / 2pm PDT SAN DIEGO , March 18, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it Mon, 18 Mar 2019 16:46:00 -0400 aTyr Pharma News Releases 8811 aTyr Pharma Announces Research Collaboration With Global Biotherapeutics Leader CSL Behring https://investors.atyrpharma.com/news-releases/news-release-details/atyr-pharma-announces-research-collaboration-global Partnership to accelerate development of IND candidates from tRNA synthetases in aTyr’s pipeline   aTyr eligible to receive up to $17 million in potential option fees SAN DIEGO , March 11, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery Mon, 11 Mar 2019 04:00:00 -0400 aTyr Pharma News Releases 8791 aTyr Pharma Announces Participation at March Investor Conferences https://investors.atyrpharma.com/news-releases/news-release-details/atyr-pharma-announces-participation-march-investor-conferences SAN DIEGO , March 04, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that management will provide an update on the ongoing clinical Mon, 04 Mar 2019 17:36:00 -0500 aTyr Pharma News Releases 8781